ReviewCNS oncology2015
Seizures in oligodendroglial tumors.
Review in CNS oncology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 1 synthesis or guideline pooled it, 33 citations in OpenAlex.
- Evidence-based recommendations for the prophylactic use of antiseizure medications (ASMs) in neurosurgery: a systematic review of guidelines.Journal of neurology · 2024Pooled it
- Aberrant neural activity in the peritumoral cortex underlies the progression of tumor-associated seizures.Nature communications · 2025Article
- Reprogramming neural-tumor crosstalk: emerging therapeutic dimensions and targeting strategies.Military Medical Research · 2025Review
- Integrated electrophysiological and genomic profiles of single cells reveal spiking tumor cells in human glioma.Cancer cell · 2024Article
- Long-term outcomes of CNS WHO grade 2 oligodendroglioma in adult patients: a single-institution experience.Discover oncology · 2024Article
- Clinical characteristics and surgical outcomes of low-grade epilepsy-associated brain tumors.Therapeutic advances in neurological disorders · 2024Article
- Unexplained Causes of Glioma-Associated Epilepsies: A Review of Theories and an Area for Research.Cancers · 2023Review
- Postoperative risk of IDH-mutant glioma-associated seizures and their potential management with IDH-mutant inhibitors.The Journal of clinical investigation · 2023Article
- Malignant Glioma.Advances in experimental medicine and biology · 2023Review
- Seizures in patients with IDH-mutated lower grade gliomas.Journal of neuro-oncology · 2022Article
- Polymorphous low-grade neuroepithelial tumor of the young: Rare tumor and review of the literature.Rare tumors · 2022Article
- The IDH1 inhibitor ivosidenib improved seizures in a patient with drug-resistant epilepsy from IDH1 mutant oligodendroglioma.Epilepsy & behavior reports · 2022Article
- Seizure in Indonesian Glioma Patients: Associated Risk Factors and Impact on Survival.Asian Pacific journal of cancer prevention : APJCP · 2021Article
- Valproic Acid: A Promising Therapeutic Agent in Glioma Treatment.Frontiers in oncology · 2021Review
- Review
- Clinical Diagnosis and Perioperative Management of Glioma-Related Epilepsy.Frontiers in oncology · 2020Review
- Clinical practice guidelines for the diagnosis and treatment of adult diffuse glioma-related epilepsy.Cancer medicine · 2019Review
- Withdrawal of antiepileptic drugs in patients with low grade and anaplastic glioma after long-term seizure freedom: a prospective observational study.Journal of neuro-oncology · 2019Observational
- Seizures and gliomas--towards a single therapeutic approach.Nature reviews. Neurology · 2016Review
- Increased cortical excitability to transcranial magnetic stimulation at the brain-tumor interface ofNeuro-oncology advancesArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Epilepsy develops in more than 70-90% of oligodendroglial tumors and represents a favorable indicator for long-term survival if present as the first clinical sign. Presence of IDH1 mutation is frequently associated with seizures in oligodendrogliomas, next to alterations of glutamate and GABA metabolism in the origin of glioma-associated epilepsy. Treatment by surgery or radiotherapy results in seizure freedom in about two-thirds of patients, and chemotherapy to a seizure reduction in about 50%. Symptomatic anticonvulsive therapy with levetiracetam and valproic acid as monotherapy are both evidence-based drugs for the partial epilepsies, and their effective use in brain tumors is supported by a large amount of additional data. Pharmacoresistance against anticonvulsants is more prevalent among oligodendrogliomas, occurring in about 40% despite polytherapy with two anticonvulsants or more. Toxic signs of anticonvulsants in brain tumors involve cognition, bone marrow and skin. Previous neurosurgery, radiation therapy or chemotherapy add to the risks of cognitive dysfunction.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.